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DOI 10.1186/s12967-015-0445-9RESEARCH Open AccessXanthine oxidase inhibition alleviates the cardiac
complications of insulin resistance: effect on low
grade inflammation and the angiotensin system
Hany M El-Bassossy1,2* and Malcolm L Watson3Abstract
Background: We have previously shown that hyperuricemia plays an important role in the vascular complications
of insulin resistance (IR). Here we investigated the effect of xanthine oxidase (XO) inhibition on the cardiac
complications of IR.
Methods: IR was induced in rats by a high fructose high fat diet for 12 weeks. Allopurinol, a standard XO inhibitor,
was administered in the last 4 weeks before cardiac hemodynamics and electrocardiography, serum glucose,
insulin, tumor necrosis factor alpha (TNFα), 8-isoprostane, uric acid, lactate dehydrogenase (LDH) and XO activity
were measured. Expression of cardiac angiotensin II (AngII) and angiotensin receptor 1 (AT1) were assessed by
immunofluorescence.
Results: IR animals had significant hyperuricemia which was inhibited by allopurinol administration. IR was
associated with impaired ventricular relaxation (reflected by a decreased diastolic pressure increment and
prolonged diastolic duration) and XO inhibition greatly attenuated impaired relaxation. IR was accompanied
by cardiac ischemia (reflected by increased QTc and T peak trend intervals) while XO inhibition alleviated the
ECG abnormalities. When subjected to isoproterenol-induced ischemia, IR hearts were less resistant (reflected
by larger ST height depression and higher LDH level) while XO inhibition alleviated the accompanying ischemia.
In addition, XO inhibition prevented the elevation of serum 8-isoprostane and TNFα, and blocked elevated AngII and
AT1 receptor expression in the heart tissue of IR animals. However, XO inhibition did not affect the developed
hyperinsulinemia or dyslipidemia.
Conclusions: XO inhibition alleviates cardiac ischemia and impaired relaxation in IR through the inhibition of
low grade inflammation and the angiotensin system.
Keywords: Metabolic syndrome, Heart, Hypertension, Xanthine oxidase, AllopurinolBackground
Insulin resistance (IR) is a key component of metabolic
syndrome (MetS). The pathogenesis of the syndrome in-
cludes multiple organs involved in the cardiovascular
system [1]. The prevalence of MetS in the US in 2002 is
estimated at 24% while in the elderly (over 60 years) the
prevalence is 44%, based upon the data from the National
Health and Nutrition Examination Survey [2]. This is* Correspondence: helbassossy@kau.edu.sa
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article, unless otherwise stated.correlated with the dramatic increase of fructose intake
in the last hundred years. Unlike other sugars, fructose
rapidly causes ATP depletion that results in nucleotide
turnover and finally generation of uric acid [3].
Although hyperuricemia is condition that frequently ac-
companies MetS, its role as a risk factor for cardiovascular
complications in MetS is debated. For decades, hyperuri-
cemia was considered as a simple result of renal dysfunc-
tion and not as a true mediator but in the late 1990s
researchers started to reevaluate hyperuricemia as a causal
risk factor for cardiovascular disease [4]. We have previ-
ously shown that direct in vitro incubation of normal iso-
lated aorta with uric acid at the same concentrationed Central. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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laxation [5].
In addition to uric acid production, the xanthine oxi-
dase (XO) enzyme generates reactive oxygen species (ROS)
through catalysing oxidation of hypoxanthine to xanthine
and then to uric acid. XO-derived reactive oxygen species
(ROS) contribute to many pathologic conditions charac-
terized by ischemia or inflammation [6]. Allopurinol is a
standard inhibitor of XO. Although this agent has been
widely used for treatment of gout for decades, in the last
fifteen years it has attracted attention for potential benefits
in cardiovascular disease [7].
Therefore, the aim of the present work was to investi-
gate whether XO represents a realistic target for inter-
vention in the context of protection of cardiovascular
dysfunction in IR and to suggest the possible mechanism
of action for protection. Data presented from this animal
study indicate potential new therapeutic strategies for
the treatment of human disease.
Methods
Animals
The study is reported in accordance with the Animals in
Research: Reporting In Vivo Experiments (ARRIVE) guide-
lines for research involving animals [8], and the Kingdom
of Saudi Arabia Research Bioethics and Regulations, con-
sistent with UK standards of care. Male Wistar rats (6 weeks
age; King Abdulaziz University, KSA) were housed (3–4
rats per cage) in clear polypropylene cages and kept under
constant environmental conditions with equal light–dark
cycle. Rats had free access to commercially available ro-
dent pellet diet and purified water.
Study overview
The experimental protocol was approved by the Unit of
Biomedical Ethics Research Committee, King Abdulaziz
University, KSA. Animals were randomly divided into three
groups (8 animals each) of control (C), IR or allopurinol-
treated insulin resistance (IR-Allo). IR was induced by add-
ing fructose (10%) to drinking water and feeding rats on
high fat high salt diet (16% crude protein, 28.2% crude fat,
2.8% crude fibre, 4.8% ash, 3.4% salt; prepared in our la-
boratories) for 12 weeks. Control animals received water
and standard diet (20% crude protein, 4% crude fat, 3.5%
crude fibre, 6% Ash, 0.5% salt). Allopurinol (20 mg.kg−1.
day−1) was administered daily in the last 4 weeks by dis-
solving in drinking water (100–110 mg.l−1) depending on
daily water consumption [9]. In previous work from our
laboratories, we have shown that eight weeks of high
fructose administration was necessary for developing sig-
nificant insulin resistance while another four weeks was
needed to produce clear vascular complications [10]. In the
present work, allopurinol was given in the last four weeks
(after establishment of IR and during the development ofvascular complications) in order to test the protective ef-
fect of allopurinol against the cardiac complications rather
than the IR.
At the end of the study animals were fasted for 8 hours.
A tail capillary droplet was used to determine the fasting
blood glucose level before rats were anaesthetized by ur-
ethane (1.5 g.kg−1, i.p.) injection [11]. Then, a microtip
catheter was inserted in the left ventricle through an
opening in the right carotid artery to continuously rec-
ord cardiac contractility while cardiac conductivity was
determined by surface electrocardiography (ECG). After
15 min recording basal cardiac contractility and conduct-
ivity, one ml blood was withdrawn from the vena cava
(through a small incision in the lower abdomen), allowed
to coagulate for 30 min at 4°C, and then centrifuged
(3000 × g, 4°C, 20 min) to separate serum. Serum was di-
vided into aliquots and stored at −20°C for later analysis
of insulin, tumor necrosis factor alpha (TNFα), adipo-
nectin, 8-isoprostane, uric acid, triglycerides and XO
activity. Rats were then injected with one ml saline to
prevent hypovolemia. After another 15 min stabilization,
acute cardiac ischemia was induced by isoproterenol
(10 μg.kg−1) injection through the femoral vein [12]. The
cardiac contractility and conductivity were continuously
recorded for 30 min after isoproterenol injection. At the
end of the experiment another millilitre of venous blood
was withdrawn for analysis of serum lactate dehydrogen-
ase (LDH) and animals were killed by an overdose of an-
aesthetic. The heart was quickly dissected and fixed in
10% neutral buffered formalin for immunofluorescence
detection of angiotensin II (AngII), angiotensin receptor
type 1 (AT1), collagen I and 4-hydroxy-2-noneal Michael
adducts (4HNE) in heart cross sections.
Biochemical analysis
Glucose was determined in tail blood samples with a glu-
cose meter (ACCU-CHEK®, Roche Diagnostics, Mannheim,
Germany). Serum insulin level was measured by enzyme-
linked immunosorbent assay (ELISA, Millipore, Billerica,
MA, USA) using plates coated with anti-rat insulin anti-
bodies. Serum TNFα and adiponectin levels were deter-
mined by ELISA using Quantikine® kits (R & D systems,
Minneapolis, MN, USA) using rat TNFα or rat adiponec-
tin and antibodies raised against rat TNF-α or rat adipo-
nectin respectively. XO activity was measured in the final
serum sample using the BioVision® assay kit (BioVision
Incorporated, Milpitas, CA, USA). Serum level of 8-
isoprostane was determined by a competitive immunoassay
8-isoprostane EIA® kit (Cayman Chemical Company, Ann
Arbor, Michigan, USA). Serum levels of uric acid and tri-
glycerides and LDH activity were determined using the
ELITech® assay kit (ELITech, Puteaux, France). Serum
level of fructosamine was determined using Quimica
Clinica® assay kit (Quimica Clinica, Amposta, Spain).
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Invasive real time recording of cardiac hemodynamics
was carried out according to the method described in a
previous report from our laboratories [13]. Following an-
aesthesia as described above the animals’ body temperature
was maintained at 37°C (measured by a rectal probe) using
controlled heating pads. A microtip pressure transducer
(SPR-320, Millar Instruments, Houston, TX, USA) was
inserted through a small incision into the right carotid
artery and advanced into the left ventricle. After 5 min
stabilization period, the signals were continuously re-
corded. The microtip catheter was connected to a Power
Lab Data Interface Module connected to a PC running
Lab Chart professional software (v8.0, AD Instruments,
Bella Vista, Australia) including the BP module. The BP
module detects and calculates the left ventricular end
ventricular systolic pressure (ESP), left ventricular end-
diastolic pressure (EDP), slope of the systolic pressure
increment (dP/dt) and slope of the diastolic pressure
decrement (−dP/dt), cystolic and diastolic duration, and
contractility index.
Electrocardiogram (ECG) recording
The standard surface ECG was recorded by the Powerlab®
system (AD Instruments, Bella Vista, Australia) connected
to a PC running LabChart professional software with the
ECG module to detect different components of the
ECG. The change in the ST segment height was used
as the index of anginal severity and the ST segment
value was defined as the mean ECG voltage 12 ms after
the S wave peak [14], and the change in ST segment value
after isoproterenol injection was calculated as the ST
depression.
Immunofluorescence Studies
Immunofluorescence staining of AngII, AT1, 4HNE and
collagen protein in rat paraffin embedded heart sections
(5 μm) was carried out according to the method used in
our previous work [15-17]. Fixed heart tissue section
slides were deparaffinized in xylene and rehydrated in
ethanol and distilled water. Then, perforation was carried
out by incubation with methanol at −20°C for 30 min
followed by washing with distilled water. Epitopes were re-
trieved (antigen retrieval) in citrate buffer for 30 min at
95°C followed by washing with phosphate buffered saline
(PBS). Slides were then immediately transferred into a hu-
midity chamber. Nonspecific binding sites were blocked
(bovine serum albumin in PBS containing 5% normal goat
serum, 1% BSA, 0.1% Triton) at room temperature for
1 h. After the blocking, sections were washed (3 x 5 min)
with PBS. Heart sections were then incubated with the
intended primary antibody diluted in blocking buffer at
4°C overnight. The sections were then washed (3 x 5 min)
with PBS followed by incubation with a fluorescentconjugated secondary antibody (diluted 1:200 in blocking
buffer) for 1 h in the dark. Then sections were washed
(3 x 5 min) with PBS and slides were dried and mounted
with ‘ProLong’ mounting media (Life Technologies,
Paisley, UK). The slides were stored in dark overnight
before examination with a Zeiss LSM 780 confocal micro-
scope (Carl Zeiss, Gottingen, Germany) at 488 and
561 nm excitation and 497–542 and 596–655 nm
emission filters). Images were acquired with identical ac-
quisition parameters, with minimum excitation and gain.
Quantitative comparisons of image fluorescence were
made with Image J software (National Institute of Health,
Bethesda, MD, USA). For presentation purposes, the level
of the confocal images were equally adjusted after the
fluorescence quantifications were carried out on unmanip-
ulated images. Sections treated with the secondary anti-
body alone did not show specific fluorescence while
incubating the primary antibody with the blocking peptide
significantly reduced the signal. The primary antibodies
used were: rabbit polyclonal anti AngII (1:2000, Phoenix
Pharmaceuticals Inc., Burlingame, CA, USA), mouse mono-
clonal anti AT1 receptor (1:133, Abcam, Cambridge, MA,
USA), mouse monoclonal anti collagen type I (1:1000,
Abcam), rabbit polyclonal anti 4HNE (1:250, Millipore,
Billerica, MA, USA). The secondary antibodies used were
Alexa Fluor (λex = 488) conjugated goat anti-mouse and
Alexa Fluor (λex = 594) conjugated goat anti-rabbit (1:200,
Life Technologies, Grand Island, NY, USA).Drugs and chemicals
The following drugs and chemicals were used: Allopurinol,
urethane (Sigma-Aldrich, St. Louis, MO, USA). Allopur-
inol was dissolved in distilled water while urethane was
dissolved in saline.Statistical analysis
Values are expressed as mean ± SEM. Statistical analysis
was carried out by analysis of variance (ANOVA) followed
by Newman-Keuls’ post hoc test using statistical software
(Prism 5, GraphPad, CA, USA).Results
Uric acid level and XO activity
High fructose high fat diet administration was associated
by a significant elevation in serum uric acid level com-
pared to control (p < 0.05, Figure 1a) while allopurinol
administration significantly inhibited the developed hy-
peruricemia (p < 0.01, Figure 1a). The serum XO activity
tended to increase in rats fed on high fructose high fat
diet while allopurinol administration significantly inhib-
ited serum XO activity compared to the high fructose
high fat diet fed group (p < 0.05, Figure 1b).
Figure 1 Effect of allopurinol (Allo) administration (20 mg.kg−1.
day−1) in the last 4 weeks on serum levels of uric acid (a) and
xanthine oxidase activity (b) in rats with high fructose high fat
(for 12 weeks) -induced insulin resistance (IR). Data are presented
as mean ± standard error of 8 animals in each group. *P < 0.05,
compared with the corresponding control group values; #P < 0.05,
##P < 0.01, compared with the corresponding IR group values; by one
way ANOVA and Newman Keuls’ post hoc test.
Table 1 Effect of xanthine oxidase inhibition by daily oral ad
high fructose high fat diet- induced insulin resistance (10% f
diet, for 12 weeks) associated changes in body weight gain a
triglycerides and the insulin resistance (IR) index
Treatment Body weight gain (%) Glucose (mg.dl−1) Fructosamin
Control 32.46 ± 5.53 72.9 ± 2.68 46.4 ± 3.26
IR 142.2 ± 29.18** 107.8 ± 5.06*** 69.0 ± 5.67**
IR-Allo 115.5 ± 16.6 98.0 ± 3.78 62.2 ± 1.83
Values are expressed as the mean ± S.E of mean; N = 6-8 animals; *P < 0.05, **P < 0.0
compared with the corresponding insulin resistance group values by One Way ANOVA
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There was no difference in the fluid consumption be-
tween the three groups. Caloric intake was 552, 742 and
735 Kcal/day/kg in the control, IR, and IR-Allo groups
respectively.
Insulin resistance (IR) development after twelve weeks
feeding on high fructose and high fat diet was evidenced
by the significantly higher weight gain (p < 0.01), glucose
(p < 0.001), insulin (p < 0.05) and triglyceride (p < 0.05)
levels in the IR group than those in the control group.
XO enzyme inhibition by allopurinol administration in
the last four weeks did not significantly affect the exag-
gerated weight gain, the developed hyperglycemia,
hyperinsulinemia or hypertriglyceridemia associated with
the high fructose and high fat diet (Table 1).
Basal cardiac hemodynamics
IR induced by high fructose high fat diet resulted in a
left ventricular diastolic dysfunction, reflected by a sig-
nificant decrease in -dP/dt (p < 0.05, Figure 2a), signifi-
cant increase in diastolic duration (p < 0.05, Figure 2b)
and a significant increase in EDP (p < 0.05, Figure 2c)
compared to the control group. XO inhibition by allo-
purinol prevented the left ventricular diastolic dysfunc-
tion associated with IR as indicated by the significant
increase in -dP/dt and decrease in diastolic duration
(both at p < 0.05, Figure 2a and b) compared with the IR
group.
IR animals did not show significant changes in cardiac
contractility index, heart rate or cycle duration com-
pared with control animals (Table 2) although XO inhib-
ition by allopurinol tended to increase the contractility
index and decrease the heart rate compared with IR ani-
mals. IR significantly increased ESP (p < 0.01, Table 3)
compared to control while XO inhibition did not affect
this increase in ESP. Neither IR nor allopurinol affected
the systolic duration or dP/dt significantly (Table 2).
Basal cardiac ECG
IR induced by high fructose high fat diet resulted in a
prolongation of cardiac repolarization, reflected by a
significant prolongation in QT, JT and T peak trendministration of allopurinol (20 mg.kg−1, last 4 weeks) on
ructose in drinking water plus 25% unsaturated fat in
nd serum levels of glucose, insulin and fructosamine and
e (mg.dl−1) Insulin (μg.l−1) Triglycerides (mg/dl) IR index
0.77 ± 0.11 48.41 ± 2.55 3.2 ± 0.44
3.81 ± 0.7* 71.97 ± 13.17* 19.28 ± 3.29**
3.76 ± 0.85 47.49 ± 4.02# 21.87 ± 5.41
1, ***P < 0.001, compared with the corresponding control group values; #P < 0.05,
and Newman Keuls post hoc test.
Figure 2 Effect of xanthine oxidase inhibition by daily oral
administration of allopurinol (20 mg.kg−1, last 4 weeks) on the
slope of cardiac diastolic pressure decrement (a), diastolic
duration (b) and end diastolic pressure (c) in rats with high
fructose high fat (for 12 weeks) -induced insulin resistance (IR).
Data are presented as mean ± standard error of 8 animals in each
group. *P < 0.05, compared with the corresponding control group
values; #P < 0.05 compared with the corresponding IR group values;
by one way ANOVA and Newman Keuls’ post hoc test.
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inhibition by allopurinol alleviated the prolonged cardiac
repolarization associated with IR as indicated by the signifi-
cant decrease in T peak interval (p < 0.05) and that the QTc
and JT was no longer significantly increased compared with
control (Figure 3). Neither IR nor allopurinol affected the
P, Q, R, S or T amplitudes significantly (Table 3).
Isoproterenol-induced acute cardiac ischemia
Intravenous injection of isoproterenol led to induction of
acute cardiac ischemia in anaesthetized rats as indicated
by ST height depression and serum lactate dehydrogenase
level elevation. Animals with IR were less resistant to acute
cardiac ischemia and were characterized by greater cardiac
ischemia as indicated by the significantly larger depression
in ST height (p < 0.01, Figure 4a) and higher serum LDH
activity (p < 0.05, Figure 4b) compared with control.
XO inhibition by allopurinol significantly alleviated the
developed acute ischemia in hearts of IR animals as indi-
cated by the significant reversal of ST height depression
and LDH overactivity compared with the IR group (all at
p < 0.05, Figure 4).
Low grade inflammation
IR induced by high fructose high fat diet was associated
with low grade inflammation and oxidative stress, reflected
by significantly higher serum levels of the oxidative stress
marker 8-isoprostane (p < 0.05, Figure 5a) and the inflam-
matory cytokine TNFα (p < 0.01, Figure 5b) compared
to control. XO inhibition by allopurinol alleviated the
low grade inflammation associated with IR as indicated
by the significantly lower serum levels of 8-isoprostane
and TNFα (both at p < 0.05) compared with IR group.
Neither IR nor allopurinol affected the serum levels
of the anti-inflammatory cytokine adiponectin signifi-
cantly (Figure 5c).
Cardiac oxidative stress and angiotensin system
Heart cross sections from animals with IR showed a sig-
nificant increase immunofluorescence for the lipid per-
oxidation product 4HNE (p < 0.05, Figure 6a) compared
with control. XO inhibition by allopurinol completely
blocked the increase in 4HNE immunofluorescence both
in heart tissue and coronary artery (both at p < 0.05,
Table 2 Effect of xanthine oxidase inhibition by daily oral administration of allopurinol (20 mg.kg−1, last 4 weeks) on
high fructose high fat diet- induced insulin resistance (10% fructose in drinking water plus 25% unsaturated fat in
diet, for 12 weeks) associated changes in left ventricle contractility index, heart rate, cycle duration, end systolic
pressure (ESP), systolic duration and maximum pressure development (dp/dt)
Treatment Contractility index (1/s) Heart rate (BPM) Cycle duration (ms) ESP (mmHg) Systolic duration (s) dp/dt (mmHg/s)
Control 122.8 ± 10.88 289.4 ± 17.3 193.9 ± 6.32 87.48 ± 2.8 81.71 ± 1.79 5497 ± 626.3
IR 129.0 ± 18.21 284.5 ± 21.0 208.9 ± 13.19 109.8 ± 5.16** 80.8 ± 3.56 7428 ± 1167
IR-Allo 169.1 ± 14.6 250.4 ± 6.3 212.3 ± 9.26 110.5 ± 8.55 85.24 ± 2.92 7334 ± 720
Values are expressed as the mean ± S.E of mean; N = 6-8 animals; **P < 0.01, compared with the corresponding control group values; by One Way ANOVA and
Newman Keuls post hoc test.
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tivation of the angiotensin system as indicated by the
significant increase in immunofluorescence for AngII
and its receptor AT1 (Figure 6c and e, both at P < 0.05).
Allopurinol completely prevented the increase in im-
munofluorescence of AngII and AT1 both in heart tissue
and coronary artery from IR animals (Figure 6c-f).
Discussion
The current study is the first to report on the protective
effect of XO inhibition against the cardiac diastolic dys-
function and ischemia associated with IR. The XO in-
hibitor allopurinol virtually abolished the development
of cardiac diastolic dysfunction and ischemia in high
fructose high fat diet-induced IR in rats without affecting
the developed hyperinsulinemia or dyslipidemia. The fol-
lowing findings support the conclusion that XO inhibition
can counteract cardiac diastolic dysfunction and ischemia
accompanying IR: (i) XO inhibition ameliorated the im-
paired left ventricular diastolic relaxation associated with
IR; (ii) the prolongation of cardiac repolarization in IR was
alleviated by XO inhibition; (iii) XO inhibition alleviated
the exaggerated cardiac ischemia following isoproterenol
injection in IR; (iv) XO inhibition alleviated the low grade
inflammation and oxidative stress associated with IR; (v)
XO inhibition blocked the IR-induced activation of the
angiotensin system both in heart tissue and coronary ar-
tery. These findings provide convincing evidence that XO
inhibition offsets the cardiac diastolic dysfunction and is-
chemia accompanying IR in addition to the associated low
grade inflammation and oxidative stress.
The predominant feature in cardiomyopathy associ-
ated with diabetes, metabolic syndrome and IR seems toTable 3 Effect of xanthine oxidase inhibition by daily oral ad
high fructose high fat diet- induced insulin resistance (10% f
diet, for 12 weeks) associated changes in P, Q, R, S and T am
Treatment P-amplitude (mV) Q-amplitude (mV) R
Control −0.011 ± 0.015 −0.134 ± 0.063 0
IR 0.057 ± 0.025 −0.18 ± 0.136 0
IR-Allo 0.041 ± 0.02 −0.005 ± 0.009 0
Values are expressed as the mean ± S.E of mean; N = 6-8 animals; No significant diffbe the left ventricular diastolic dysfunction as shown in the
present study and indicated in previous works [18,19].
Ventricular relaxation is considered as an active process
that depends mainly on the intracellular calcium uptake
by the endoplasmic reticulum during diastole [20]. We
reasoned that XO inhibition would minimize the cardiac
dysfunction associated with IR. The validity of this as-
sumption was ascertained in this work because allopurinol,
the standard XO inhibitor, prevented the left ventricular
diastolic dysfunction associated with IR as indicated by the
significant increase in -dP/dt and decrease in diastolic dur-
ation compared with the IR group. In agreement with this,
XO activation has been shown to contribute to left ven-
tricular diastolic dysfunction in an experimental model of
cocaine-induced diastolic dysfunction [21].
Prolongation of cardiac repolarization is an important
cardiovascular risk factor in several diseases, including
diabetes mellitus and infarction [22]. Animals with IR in
this study have shown prolonged cardiac repolarization
reflected by the significant increase in QTc, JT and T
peak trend intervals compared to control. The role of
prolonged repolarization in type II diabetes is not well
established, although repolarization heterogeneity is ob-
served [23]. In our work we demonstrate normalization
of the repolarization by allopurinol, implicating xanthine
oxidase-derived ROS. The molecular mechanism for pro-
longed repolarization in IR is not clear, but appears to
involve ROS-dependent oxidation and activation of p90
ribosomal S6 kinase and inhibition of voltage gated K+
channels [24], and/or Ca/calmodulin-dependent protein
kinase II and cardiac sodium channels [25].
The results of the present study show that animals with
IR are less resistant to isoproterenol-induced acute cardiacministration of allopurinol (20 mg.kg−1, last 4 weeks) on
ructose in drinking water plus 25% unsaturated fat in
plitudes
-amplitude (mV) S-amplitude (mV) T-amplitude (mV)
.346 ± 0.077 −0.17 ± 0.07 0.053 ± 0.035
.67 ± 0.148 −0.42 ± 0.21 0.14 ± 0.08
.527 ± 0.085 −0.28 ± 0.07 0.155 ± 0.046
erences were detected by One Way ANOVA.
Figure 3 Effect of xanthine oxidase inhibition by daily oral
administration of allopurinol (20 mg.kg−1, last 4 weeks) on the
slope of electrocardiograph QT (a), JT (b) and T peak trend (c)
intervals in rats with high fructose high fat (for 12 weeks)
induced insulin resistance (IR). Data are presented as mean ±
standard error of 8 animals in each group. *P < 0.05, compared with
the corresponding control group values; #P < 0.05compared with the
corresponding IR group values; by one way ANOVA and Newman
Keuls’ post hoc test.
Figure 4 Effect of xanthine oxidase inhibition by daily oral
administration of allopurinol (20 mg.kg−1, last 4 weeks) on the ST
height depression (a) and serum lactate dehydrogenase level (b)
following isoproterenol-induced acute cardiac ischemia in rats with
high fructose high fat (for 12 weeks) induced insulin resistance (IR).
Data are presented as mean ± standard error of 8 animals in each
group. *P < 0.05, **P < 0.01, compared with the corresponding control
group values; #P < 0.05 compared with the corresponding IR group
values; by one way ANOVA and Newman Keuls’ post hoc test.
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Figure 5 Effect of xanthine oxidase inhibition by daily oral
administration of allopurinol (20 mg.kg−1, last 4 weeks) on
serum levels of TNFα (a), 8-isoprostane (b) and adiponectin
(c) in rats with high fructose high fat (for 12 weeks) induced
insulin resistance (IR). Data are presented as mean ± standard error of
8 animals in each group. *P < 0.05, compared with the corresponding
control group values; #P < 0.05 compared with the corresponding IR
group values; by one way ANOVA and Newman Keuls’ post hoc test.
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in ST height and higher serum LDH activity compared
with control. This is in agreement with clinical literature
where MetS is associated with a high incidence of coron-
ary atheroma and an increased risk of fatal coronary
events [26]. The fructose-induced model of MetS was as-
sociated with clear arterial atheroma in previous work of
our laboratories [17]. In the present study, XO inhibition
by allopurinol significantly alleviated the developed ische-
mia in hearts of IR animals as indicated by the signifi-
cant decrease in ST height depression and LDH activity
compared with animals not receiving allopurinol. This
is in accordance with the reported anti-ischemic ac-
tivities for allopurinol in patients with ischemic heart
disease [27].
The protective effect of XO inhibition against cardiac
diastolic dysfunction and ischemia in animals with IR
seems to be direct cardiovascular protection rather than
affecting IR itself, because XO inhibition did not have a
significant effect on the IR index. However, it did signifi-
cantly alleviate the cardiac diastolic dysfunction and is-
chemia in animals with IR. This also provides proof for
the assumption that hyperuricemia and XO activation
are independent risk factors for cardiovascular disease in
IR. Numerous current epidemiological studies point to a
possible role of uric acid as an independent risk factor
for cardiovascular complications in metabolic syndrome,
but without definitive conclusions [4].
The mechanism(s) by which XO inhibition alleviates car-
diac diastolic dysfunction and ischemia in animals with IR
could be by a reduction of the associated hyperuricemia
and oxidative stress. Although uric acid has antioxidant ef-
fects extracellularly, it stimulates inflammatory and oxida-
tive stress mechanisms inside the cell [28]. This results in
an inhibition of endothelial dependent relaxation and nitric
oxide (NO) production [29]. We have previously shown
that in vitro incubation with uric acid at the concentration
observed in MetS animals impaired endothelial relaxation
in isolated normal aorta [5]. In the present study, we found
that allopurinol completely prevented hyperuricemia in an-
imals with IR.
Oxidative stress and low-grade inflammation are clearly
involved in pathogenesis of the IR and MetS and its com-
plications [30]. The reactive oxygen species (ROS) gener-
ated by enzymes including the XO in IR and MetS interact
Figure 6 Effect of xanthine oxidase inhibition by daily oral administration of allopurinol (20 mg.kg−1, last 4 weeks) on 4-hydroxy-2-
noneal Michael Adducts (4HNE), angiotensin II (AngII) and angiotensin receptor type 1 (AT1) immunofluorescence in heart (a, c and e
respectively) and coronary artery (b, d and f respectively) sections from rats with high fructose high fat (for 12 weeks) induced insulin
resistance (IR). Data are presented as mean ± standard error of 8 animals in each group. *P < 0.05, compared with the corresponding control
group values; #P < 0.05 compared with the corresponding IR group values; by one way ANOVA and Newman Keuls’ post hoc test. Micrographs at
the top are representative fluorescence images of heart and coronary artery cross sections immunofluorescence stained by 4HNE, AngII or AT1
antibodies followed by Alexa fluor conjugated secondary antibodies.
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loss of function [31]. In the cardiovascular system, ROS
can impair relaxation by mopping up of released NO, un-
coupling of endothelial NO synthase and activating tran-
scription of inflammatory genes [32]. We have previously
shown elevated aortic ROS [33], nuclear factor kappa B ac-
tivation and serum TNFα [17] in animal models of meta-
bolic syndrome that were significantly correlated with
impaired NO production and endothelial dependent re-
laxation [34]. In the present study, animals with IR had
significantly higher serum levels of the oxidative stress
marker 8-isoprostane and TNFα while XO inhibition
by allopurinol completely prevented these elevations. In
addition, XO inhibition completely blocked increases in
the lipid peroxidation product 4HNE both in heart tissue
and coronary artery. This is consistent with previous work
where allopurinol alleviated the elevated liver malondial-
dehyde and TNFα associated with acute liver failure in-
duced by thioacetamide in rats [35].The angiotensin system is one of the most important
oxidative stress systems activated in MetS. The major ef-
fector peptide in the system is AngII, which binds to
AT1 or AT2 receptors to exert different biological func-
tions. Binding of AngII to AT1 has been shown to pro-
duce the second messengers inositol trisphosphate and
diacylglycerol which lead to stimulation of reactive oxy-
gen species and vasoconstriction in numerous previous
reports (reviewed by Frigolet et al. [36]). In the present
work, XO inhibition completely prevented the increase
in AngII and AT1 in both heart tissue and coronary ar-
tery from IR animals. This is in accordance with a previ-
ous study showing that allopurinol attenuated oxidative
stress and cardiac dysfunction induced by AngII infusion
in mice [37].
The possibility that modulation in serum lipids contributed
to IR-XO cardiac dysfunction was also examined. Dyslipid-
emia is associated with increased cardiovascular mortality
and morbidity [38]. Our findings showed that IR was
El-Bassossy and Watson Journal of Translational Medicine  (2015) 13:82 Page 10 of 11characterized by hypertriglyceridemia while XO inhibition
completely prevented hypertriglyceridemia associated
with IR. This is in accordance with previous reports
where allopurinol inhibited the hypertriglyceridemia in
diabetic animals [39]. These observations suggest that the
cardioprotective effect of XO inhibition may be mediated,
at least in part, by amelioration of hypertriglyceridemia.
Conclusions
XO inhibition by allopurinol alleviates cardiac diastolic
dysfunction and ischemia associated with IR. Inhibition of
hyperuricemia, low grade inflammation and the angioten-
sin system are suggested potential mechanisms for the
observed cardiac protection. It remains to be determined
whether the cardiac dysfunction observed is the conse-
quence of one cytokine or of the combinatorial effects of
multiple mediators, and the effect of blocking individual
cytokines in this model may provide further mechanistic
insight. The findings from this study suggest that xanthine
oxidase may provide a novel drug target for the treatment
of cardiac complications associated with insulin resistance
and diabetes.
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